Amgen: MariTide And Osteoporosis Sales Fuel The Rally (NASDAQ:AMGN)

分组1 - The article discusses Amgen's Q3 results and the efficacy of MariTide in its Phase 2 trial [1] - Amgen's performance is under scrutiny to determine if it can sustain its recent rally into 2026 [1] 分组2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [2] - The company aims to simplify investment strategies for both seasoned and novice investors, fostering a community of informed investors [2]